Acta Vet. Brno 2022, 91: 363-373

https://doi.org/10.2754/avb202291040363

Effectiveness of therapy with low-dosage masitinib on pulmonary hypertension in dogs: a pilot study

Yu Sahashi1,2, Yoshiaki Hikasa2

1Sahashi Veterinary Hospital, Inagawa, Kawabe-gun, Hyogo, Japan
2Tottori University, Joint Graduate School of Veterinary Sciences, Department of Clinical Veterinary Science, Tottori, Japan

Received May 23, 2022
Accepted October 10, 2022

References

1. Arita S, Arita N, Hikasa Y 2013: Therapeutic effect of low-dose imatinib on pulmonary arterial hypertension in dogs. Can Vet J 54: 255-261
2. Atkinson KJ, Fine DM, Thombs LA, Gorelick JJ, Durham HE 2009: Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs. J Vet Intern Med 23: 1190-1196 <https://doi.org/10.1111/j.1939-1676.2009.0390.x>
3. Bach JF, Rozanski EA, MacGregor J, Betkowski JM, Rush JE 2006: Retrospective evaluation of sildenafil citrate as a therapy for pulmonary hypertension in dogs. J Vet Intern Med 20: 1132-1135 <https://doi.org/10.1111/j.1939-1676.2006.tb00711.x>
4. Barst RJ 2005: PDGF signaling in pulmonary arterial hypertension. J Clin Invest 115: 2691-2694 <https://doi.org/10.1172/JCI26593>
5. Bonkobara M 2015: Dysregulation of tyrosine kinases and use of imatinib in small animal practice. Vet J 205: 180-188 <https://doi.org/10.1016/j.tvjl.2014.12.015>
6. Borgarelli M, Savarino P, Crosara S, Santilli RA, Chiavegato D, Poggi M, Bellino C, La Rosa G, Zanatta R, Haggstrom J, Tarducci A 2008: Survival characteristics and prognostic variables of dogs with mitral regurgitation attributable to myxomatous valve disease. J Vet Intern Med 22: 120-128 <https://doi.org/10.1111/j.1939-1676.2007.0008.x>
7. Brown AJ, Davison E, Sleeper MM 2010: Clinical efficacy of sildenafil in treatment of pulmonary arterial hypertension in dogs. J Vet Intern Med 24: 850-854 <https://doi.org/10.1111/j.1939-1676.2010.0517.x>
8. Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Castéran N, Borge L, Hajem B, Lermet A, Sippl W, Voisset E, Arock M, Auclair C, Leventhal PS, Mansfield CD, Moussy A, Hermine O 2009: Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One 4: e7258 <https://doi.org/10.1371/journal.pone.0007258>
9. Frost AE, Barst RJ, Hoeper MM, Chang HJ, Frantz RP, Fukumoto Y, Galié N, Hassoun PM, Klose H, Matsubara H, Morrell NW, Peacock AJ, Pfeifer M, Simonneau G, Tapson VF, Torres F, Dario Vizza C, Lawrence D, Yang W, Felser JM, Quinn DA, Ghofrani HA 2015: Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. J Heart Lung Transplant 34: 1366-1375 <https://doi.org/10.1016/j.healun.2015.05.025>
10. Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, Shapiro S, Golpon H, Toshner M, Grimminger F, Pascoe S 2010: Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 182: 1171-1177 <https://doi.org/10.1164/rccm.201001-0123OC>
11. Greco DS, Biller B, Van Liew CH 2003: Measurement of plasma atrial natriuretic peptide as an indicator of prognosis in dogs with cardiac disease. Can Vet J 44: 293-297
12. Hatano M, Yao A, Shiga T, Kinugawa K, Hirata Y, Nagai R 2010: Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension. Int Heart J 51: 272-276 <https://doi.org/10.1536/ihj.51.272>
13. Humbert M, Sitbon O, Simonneau G 2004: Treatment of pulmonary arterial hypertension. N Engl J Med 351: 1425-1436 <https://doi.org/10.1056/NEJMra040291>
14. Johnson L, Boon J, Orton EC 1999: Clinical characteristics of 53 dogs with Doppler-derived evidence of pulmonary hypertension: 1992-1996. J Vet Intern Med 13: 440-447
15. Keene BW, Atkins CE, Bonagura JD, Fox PR, Häggström J, Fuentes VL, Oyama MA, Rush JE, Stepien R, Uechi M 2019: ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. J Vet Intern Med 33: 1127-1140 <https://doi.org/10.1111/jvim.15488>
16. Kellihan HB, Stepien RL 2010: Pulmonary hypertension in dogs: diagnosis and therapy. Vet Clin North Am Small Anim Pract 40: 623-641 <https://doi.org/10.1016/j.cvsm.2010.03.011>
17. Kovács A, Oláh A, Lux Á, Mátyás C, Németh BT, Kellermayer D, Ruppert M, Török M, Szabó L, Meltzer A, Assabiny A, Birtalan E, Merkely B, Radovits T 2015: Strain and strain rate by speckle-tracking echocardiography correlate with pressure-volume loop-derived contractility indices in a rat model of athlete’s heart. Am J Physiol Heart Circ Physiol 308: H743-H748 <https://doi.org/10.1152/ajpheart.00828.2014>
18. Leong ZP, Hikasa Y 2018: Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats. Vascul Pharmacol 110: 31-41 <https://doi.org/10.1016/j.vph.2018.07.002>
19. Leong ZP, Hikasa Y 2019: Effects of masitinib compared with tadalafil for the treatment of monocrotaline-induced pulmonary arterial hypertension in rats. Vascul Pharmacol 122-123: 106599 <https://doi.org/10.1016/j.vph.2019.106599>
20. Leong ZP, Okida A, Higuchi M, Yamano Y, Hikasa Y 2018: Reversal effects of low-dose imatinib compared with sunitinib on monocrotaline-induced pulmonary and right ventricular remodeling in rats. Vascul Pharmacol 100: 41-50 <https://doi.org/10.1016/j.vph.2017.10.006>
21. Mandegar M, Fung YC, Huang W, Remillard CV, Rubin LJ, Yuan JX 2004: Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. Microvasc Res 68: 75-103 <https://doi.org/10.1016/j.mvr.2004.06.001>
22. Maihöfer NA, Suleiman S, Dreymüller D, Manley PW, Rossaint R, Uhlig S, Martin C, Rieg AD 2017: Imatinib relaxes the pulmonary venous bed of guinea pigs. Respir Res 18: 32 <https://doi.org/10.1186/s12931-017-0514-0>
23. Marech I, Patruno R, Zizzo N, Gadaleta C, Introna M, Zito AF, Gadaleta CD, Ranieri G 2014: Masitinib (AB1010), from canine tumor model to human clinical development: where we are? Crit Rev Oncol Hematol 91: 98-111 <https://doi.org/10.1016/j.critrevonc.2013.12.011>
24. Mikawa S, Nagakawa M, Ogi H, Akabane R, Koyama Y, Sakatani A, Ogawa M, Miyakawa H, Shigemoto J, Tokuriki T, Toda N, Miyagawa Y, Takemura N 2020: Use of vertebral left atrial size for staging of dogs with myxomatous valve disease. J Vet Cardiol 30: 92-99 <https://doi.org/10.1016/j.jvc.2020.06.001>
25. Montani D, Perros F, Gambaryan N, Girerd B, Dorfmuller P, Price LC, Huertas A, Hammad H, Lambrecht B, Simonneau G, Launay JM, Cohen-Kaminsky S, Humbert M 2011: C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 184: 116-123 <https://doi.org/10.1164/rccm.201006-0905OC>
26. Moonarmart W, Boswood A, Luis Fuentes V, Brodbelt D, Souttar K, Elliott J 2010: N-terminal pro B-type natriuretic peptide and left ventricular diameter independently predict mortality in dogs with mitral valve disease. J Small Anim Pract 51: 84-96 <https://doi.org/10.1111/j.1748-5827.2009.00889.x>
27. Nakamura K, Akagi S, Ogawa A, Kusano KF, Matsubara H, Miura D, Fuke S, Nishii N, Nagase S, Kohno K, Morita H, Oto T, Yamanaka R, Otsuka F, Miura A, Yutani C, Ohe T, Ito H 2012: Pro-apoptotic effects of imatinib on PDGF-stimulated pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. Int J Cardiol 159: 100-106 <https://doi.org/10.1016/j.ijcard.2011.02.024>
28. Pariaut R, Saelinger C, Strickland KN, Beaufrčre H, Reynolds CA, Vila J 2012: Tricuspid annular plane systolic excursion (TAPSE) in dogs: reference values and impact of pulmonary hypertension. J Vet Intern Med 26: 1148-1154 <https://doi.org/10.1111/j.1939-1676.2012.00981.x>
29. Perros F, Montani D, Dorfmüller P, Durand-Gasselin I, Tcherakian C, Le Pavec J, Mazmanian M, Fadel E, Mussot S, Mercier O, Hervé P, Emilie D, Eddahibi S, Simonneau G, Souza R, Humbert M 2008: Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 178: 81-88 <https://doi.org/10.1164/rccm.200707-1037OC>
30. Rabinovitch M 2008: Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 118: 2372-2379 <https://doi.org/10.1172/JCI33452>
31. Reinero C, Visser LC, Kellihan HB, Masseau I, Rozanski E, Clercx C, Williams K, Abbott J, Borgarelli M, Scansen BA 2020: ACVIM consensus statement guidelines for the diagnosis, classification, treatment, and monitoring of pulmonary hypertension in dogs. J Vet Intern Med 34: 549-573 <https://doi.org/10.1111/jvim.15725>
32. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, Grimminger F 2005: Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115: 2811-2821 <https://doi.org/10.1172/JCI24838>
33. Serres F, Pouchelon JL, Poujol L, Lefebvre HP, Trumel C, Daste T, Sampedrano CC, Gouni V, Tissier R, Hawa G, Chetboul V 2009: Plasma N-terminal pro-B-type natriuretic peptide concentration helps to predict survival in dogs with symptomatic degenerative mitral valve disease regardless of and in combination with the initial clinical status at admission. J Vet Cardiol 11: 103-121 <https://doi.org/10.1016/j.jvc.2009.07.001>
34. Soria JC, Massard C, Magné N, Bader T, Mansfield CD, Blay JY, Bui BN, Moussy A, Hermine O, Armand JP 2009: Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers. Eur J Cancer 45: 2333-2341 <https://doi.org/10.1016/j.ejca.2009.05.010>
35. Stepien RL 2009: Pulmonary arterial hypertension secondary to chronic left-sided cardiac dysfunction in dogs. J Small Anim Pract 50 Suppl 1: 34-43 <https://doi.org/10.1111/j.1748-5827.2009.00802.x>
36. Tei C 1995: New non-invasive index for combined systolic and diastolic ventricular function. J Cardiol 26: 135-136
37. Vazquez de Prada JA, Ruano J, Martin-Duran R, Larman M, Zueco J, Ortiz de Murua JA, Torres A, Figueroa A 1987: Noninvasive determination of pulmonary arterial systolic pressure by continuous wave Doppler. Int J Cardiol 16: 177-184 <https://doi.org/10.1016/0167-5273(87)90249-X>
front cover
  • ISSN 0001-7213 (printed)
  • ISSN 1801-7576 (electronic)

Current issue

Indexed in DOAJ

Archive